RSS
Healthcare: Study: Modest 3.1% progress for pharmaceutical market in 2012
The Romanian pharmaceutical market ranked to 2.63 billion euro, on the rise by 3.1% against 2011
The Romanian pharmaceutical market ranked to 2.63 billion euro, on the rise by 3.1% compared to 2011, according to data analysis and study company Cegedim Romania, which estimates a possible drop of European currency value for 2013.
“Difficulties in the market have affected even the most powerful companies and the prognosis remains modest for 2013, rise of 1.4% in lei meaning a drop in euro or dollars. The most important problem is not necessarily at company level, but the quality and availability of medicines for patients, as well as medical services in general. Market financing through claw-back is not sustainable and the new authorities have the difficult mission to find solutions both on a short and average term, ‘ said Petru Craciun, general manager of Cegedim Romania in a press release.
In lei, last year’s increase was 8.3%, a little under the Cegedim prognosis of 8.9%, the market value reaching 11.71 billion lei.“The drop of the quarterly growth rate from 5.2% in the third quarter to 3.9% in the fourth quarter, combined with the annual growth rate of 8.3% in lei for 2012, a little under the 8.9% prognosis, clearly showing the temperation tendency of the pharmaceutical market, but because of the evolution of constrictions and needs,” Craciun said.
Compared to increase rates of the last five quarters a stagnation in units can be seen (0.4%), a slight increase of treatment days (2.4%) and in lei value (3.9%).According to Cegedim, the market will suffer as a result of measures to reduce public support and extending payment terms, only some patients maintaining at the previous treatment level. On distribution channels, increase rates in euro were 2.6% for drug stores, (2.27 billion euro) and 6.4% for hospitals (356 million euro).
Per segments the value of medicines issued based on prescriptions was 1.8% higher than in 2011 – 1.89 billion euro, and that of products without prescription grew by 6.6% at 375 million euro.
As for the top of the main ten companies, it is headed by Sanofi (including Zentiva and Sanofi-Pasteur) with sales of 978.3 million lei and a share of 8.4%, followed by Hoffmann La Roche with 884.9 million lei and 7.6% the market and Novartis, with 747.5 million lei and a share of 6.4% of the market.
The classification of the firstv10 players is completed by GlaxoSmithKline, Servier, Pfizer, Astra Zeneca, Merck&Co, Ranbaxy and Abbott with market shares between 5.4 and 3.4%.
At the level 11-20 there are Antibiotice Iasi, KRKA, Johnson&Johnson, Teva, Bristol Myers Squibb, Menarini, Bayer, Labormed, Eli Lilly and Gedeon Richter, with market shares between 2.5 and 1.4%.